Skip to main content

Table 2 Summary baseline table of studies comparing AIAT vs. IIAT

From: Pseudomonas infections among hospitalized adults in Latin America: a systematic review and meta-analysis

Author YearCountry (Enrollment Period)Study DesignTotal Follow-upTotal NPathogenSite of InfectionMean Age (SD), yr% Male% IIATTimeliness of AIATSusceptibility reported
Araujo 2016 [12]Brazil (2009–2012; 2014–2014)CC~ 55 days236MDR and Non-MDR PABSI: 100%52.7 (22.9)70.336< 24 hYes
Dantas 2014 [15]Brazil (2009–2011)RC~ 55.4 days120Resistant and susceptible PABSI: 100%51.5 (3.2)63.328.3NRNR
Gonzales 2014 [13]Colombia (2005–2008)RC; CC30 days164PARS: 37.5%; Central venous catheter 28.6%56 (33.5)67.150< 48 hYes
Pinheiro 2008 [17]Brazil (2006–2007)RC; CC30 days131PARS: 65.6%; BSI: 18.3%; UTI: 11.5%64.2 (18.4)50.437.3NRYes
Tuon 2012 [16]Brazil (2006–2009)CC30 days77CRPA, CSPABSI: 100%48.072.752< 24 hYes
Rossi 2017 [14]Brazil (2009–2012)CCNR157PA 100%Unknown: 62.42; RS: 17.19; BSI: 13.3752.0 (24.5)66.931.2NRYes
  1. AIAT Appropriate initial antibiotic therapy; BSI Bacteremia/Bloodstream infection; CC Case-control; CRPA Carbapenem-resistant Pseudomonas aeruginosa; CSPA Carbapenem-susceptible Pseudomonas aeruginosa; H hour; IIAT Inappropriate initial antibiotic therapy; MDR Multidrug resistant; N Number; NR Not reported; PA Pseudomonas aeruginosa; RC Retrospective; RS Respiratory; UTI Urinary tract infection; Yr Year